Navigation

Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab

Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs

Status: History
Expected date of issue: June 2011
Referral date: November 2008
Process: STA
Topic area:
  • Musculoskeletal
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Sally Doss
Project manager: Kate Moore
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 2 July 2010
1st appraisal committee meeting: 28 September 2010
2nd appraisal committee meeting 25 November 2010
3rd appraisal committee meeting: 24 March 2011
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

 

Manufacturers/sponsors

  • MSD (golimumab)

 

Patient/carer groups

  • National Rheumatoid Arthritis Society

 

Professional groups

  • British Health Professionals in Rheumatology
  • British Society for Rheumatology
  • Primary Care Rheumatology Society
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

 

Others

  • Department of Health
  • Northumberland Care Trust
  • Torbay Care Trust
  • Welsh Assembly Government

 

General

  • Commissioning Support Appraisals Service
  • NHS Quality Improvement Scotland

 

Possible comparator manufacturers

  • Abbott Laboratories (adalimumab)
  • AstraZeneca UK (chloroquine)
  • Bristol Myers Squibb (abatacept)
  • Pfizer (methotrexate, sulfasalazine)
  • Roche Products (rituximab, tocilizumab)
  • Sanofi Aventis (hydroxychloroquine, leflunomide, sodium aurothiomalate)
  • MSD (infliximab)
  • UCB Pharma (certolizumab pegol)

 

Relevant research groups

  • None

 

Evidence review groups

  • National Institute for Health Research Health Technology Assessment Programme
  • School of Health & Related Research Sheffield (ScHARR)

 

Associated guideline groups

  • National Clinical Guideline Centre (NCGC)

 

Associated public health groups

  • None

Top


 

Project history

Date Update
3 June 2009 The appraisal was suspended because the manufacturer informed NICE that not all information is available to complete an evidence submission at this stage.

29 December 2010

 

 

At its first discussion of golimumab in the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs the Appraisal Committee recommended that NICE ask for further evidence to be provided by the manufacturer (Schering-Plough, part of Merck Sharpe and Dohme).

At its second meeting the Appraisal Committee considered the evidence and a review of it by the Evidence Review Group. The evidence provided by the manufacturer was inadequate as a basis for the Appraisal Committee to make final recommendations.

The Institute has therefore decided to suspend the appraisal of golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying antirheumatic drugs while the manufacturer is provided with a final opportunity to provide evidence to support the Appraisal Committee in formulating recommendations.

No documentation will be issued at this stage.

The Appraisal Committee will continue consideration of this topic at the earliest possible opportunity. We will confirm the date of the next Committee meeting as soon as we can.

Top


 

Key documents

This page was last updated: 08 July 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.